



Queensland University of Technology
Brisbane Australia

This may be the author's version of a work that was submitted/accepted for publication in the following source:

[Wang, Joshua, Beecher, Kate, Chehrehasa, Fatemeh, Belmer, Arnauld, & Bartlett, Selena](#)

(2021)

The neuroinflammation biomarker translocator protein (TSPO) plays a role in sucrose overconsumption in mice. In *Australian and New Zealand Obesity Society 2021 Annual Scientific Meeting*, 2021-07-20 - 2021-07-22.

This file was downloaded from: <https://eprints.qut.edu.au/212253/>

© Consult author(s) regarding copyright matters

This work is covered by copyright. Unless the document is being made available under a Creative Commons Licence, you must assume that re-use is limited to personal use and that permission from the copyright owner must be obtained for all other uses. If the document is available under a Creative Commons License (or other specified license) then refer to the Licence for details of permitted re-use. It is a condition of access that users recognise and abide by the legal requirements associated with these rights. If you believe that this work infringes copyright please provide details by email to qut.copyright@qut.edu.au

License: Creative Commons: Attribution-Noncommercial 4.0

Notice: *Please note that this document may not be the Version of Record (i.e. published version) of the work. Author manuscript versions (as Submitted for peer review or as Accepted for publication after peer review) can be identified by an absence of publisher branding and/or typeset appearance. If there is any doubt, please refer to the published source.*

<https://static1.squarespace.com/static/5e3b5875edc1485d14d6fe3a/t/60f672776c8d901dda442adf/1626763907919/ANZOS+2021+-+Program+Book+Final+20.07.21.pdf>

The neuroinflammation biomarker, translocator protein (TSPO), plays a role in sucrose overconsumption in mice

Joshua Wang¹, Kate Beecher¹, Fatemeh Chehrehasa², Arnauld Belmer¹, Selena E Bartlett¹

1. Addiction Neuroscience and Obesity laboratory, School of Clinical Sciences, Faculty of Health, Translational Research Institute, Queensland University of Technology, Brisbane, QLD, Australia

2. Addiction Neuroscience and Obesity laboratory, School of Biomedical Sciences, Faculty of Health, Translational Research Institute, Queensland University of Technology, Brisbane, QLD,

Australia Sugar overconsumption is a major cause of obesity. Existing pharmacotherapeutics for obesity have failed to stop the growing prevalence of this disease. Emerging research suggests that neuroinflammation mediates the pathogenesis of diet-induced obesity.

Neuroinflammation has been implicated in many neuropathologies by measuring the expression of a neuroinflammatory biomarker – the translocator protein (TSPO). Etifoxine, a TSPO partial agonist and FDA approved anxiolytic, is one of the few antipsychotic medications that does not cause weight gain. Given the proposed role of TSPO in anorexia and obesity, we hypothesized that etifoxine may have therapeutic potential in the treatment of sugar overconsumption. In this study, C57/BL6 mice consumed a 25% sucrose solution for 12 weeks starting at 6 weeks of age following common a common addiction consumption paradigm. After 6 and 12 weeks of sucrose consumption, two groups of 12 mice were treated with either intraperitoneal injections of etifoxine (20 mg/kg or 50 mg/kg) or the TSPO specific antagonist PK11195 (1mg/kg or 10 mg/kg). A single injection of 50 mg/kg etifoxine reduced sucrose consumption both 30 mins and 2 hrs into the drinking session, after 4 and 12 weeks of sucrose consumption. In contrast, PK11195 treatment did not alter sucrose consumption at either dose after 4 or 12 weeks of sucrose consumption. To assess if the effect seen from etifoxine is TSPO specific, a third group of 12 mice were pre-treated with 10 mg/kg PK11195 30 minutes prior to receiving a 50 mg/kg etifoxine injection. Pre-treatment with PK11195 blocked the consumption-reducing effect of etifoxine. Together, these results demonstrate that etifoxine acts through TSPO to reduce sucrose consumption in sucrose overconsuming mice. Given the well-documented safety profile of etifoxine, this study provides preliminary supporting evidence for its potential repurposing as an anti-obesity medication.

1. Jacques, A., Chaaya, N., Beecher, K., Ali, S. A., Belmer, A., & Bartlett, S. (2019). The impact of sugar consumption on stress driven, emotional and addictive behaviors. *Neuroscience and Biobehavioral Reviews*, 103, 178–199. <https://doi.org/10.1016/j.neubiorev.2019.05.021>
2. Nuss, P., Ferreri, F., & Bourin, M. (2019). An update on the anxiolytic and neuroprotective properties of etifoxine: From brain GABA modulation to a whole-body mode of action. *Neuropsychiatric Disease and Treatment*, 15, 1781–1795. <https://doi.org/10.2147/NDT.S200568>
3. Costa, B., Cavallini, C., Da Pozzo, E., Taliani, S., Da Settimo, F., & Martini, C. (2017). The Anxiolytic Etifoxine Binds to TSPO Ro5-4864 Binding Site with Long Residence Time Showing a High Neurosteroidogenic Activity. *ACS Chemical Neuroscience*, 8(7), 1448–1454. <https://doi.org/10.1021/acscchemneuro.7b00027>
4. [https://doi.org/10.1016/s0014-2999\(00\)00760-3](https://doi.org/10.1016/s0014-2999(00)00760-3) Tuisku, J., Plavén-Sigray, P., Gaiser, E. C., Airas, L., Al-Abdulrasul, H., Brück, A., Carson, R. E., Chen, M.-K., Cosgrove, K. P., Ekblad, L.,

Esterlis, I., Farde, L., Forsberg, A., Halldin, C., Helin, S., Kosek, E., Lekander, M., Lindgren, N., Marjamäki, P.,... Cervenka, S. (2019). Effects of age, BMI and sex on the glial cell marker TSPO - a multicentre [11C]PBR28 HRRT PET study. *European Journal of Nuclear Medicine and Molecular Imaging*, 46(11), 2329–2338. <https://doi.org/10.1007/s00259-019-04403-7>

5. Ibrahim, K. S., Craft, J. A., Biswas, L., Spencer, J., & Shu, X. (2020). Etifoxine reverses weight gain and alters the colonic bacterial community in a mouse model of obesity. *Biochemical Pharmacology*, 180, 114151. <https://doi.org/10.1016/j.bcp.2020.114151>